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Prestroke and Poststroke Antithrombotic Therapy
in Patients With Atrial Fibrillation
Results From a Nationwide Cohort
Anna Gundlund, MD; Ying Xian, MD, PhD; Eric D. Peterson, MD, MPH; Jawad H. Butt, MD; Kasper Gadsbøll, MD; Jonas Bjerring Olesen, MD, PhD;
Lars Køber, MD, DMSc; Christian Torp-Pedersen, MD, DMSc; Gunnar H. Gislason, MD, PhD; Emil Loldrup Fosbøl, MD, PhD
Abstract
IMPORTANCE Antithrombotic therapies are effective in both primary and secondary stroke
prophylaxis in high-risk patients with atrial fibrillation (AF), but they are often underused in
community practice.
OBJECTIVE To examine prestroke and poststroke antithrombotic treatment patterns and long-term
outcomes in patients with AF presenting with ischemic stroke.
DESIGN, SETTING, AND PARTICIPANTS A retrospective cohort study of Danish patients with AF,
with a prestroke CHA2DS2-VASc score of 1 or higher for men and 2 or higher for women, and
presenting with ischemic stroke was conducted from January 1, 2004, to January 31, 2017. Data on
hospital admission, prescription fillings, and vital status were assessed using several Danish
nationwide registries.
EXPOSURES Patients who survived 100 days after discharge were divided into 3 groups according
to poststroke antithrombotic therapy: oral anticoagulation (OAC) therapy, antiplatelet therapy alone,
or no antithrombotic therapy.
MAIN OUTCOMES AND MEASURES Long-term outcomes (thromboembolic events and bleeding
complications) were examined using multivariable Cox regression analyses across the 3 groups.
RESULTS Among 30 626 patients with AF admitted with ischemic stroke, 11 139 patients (36.3%)
received OAC therapy (44.3% female; median age, 79 years [interquartile range, 73-85 years]), 11 874
(38.8%) received antiplatelet therapy alone (55.0% female; median age, 82 years [interquartile
range, 75-88 years]), and 7613 (24.9%) received no antithrombotic therapy before stroke (53.8%
female; median age, 80 years [interquartile range, 71-86 years]). Following stroke, 31.3% of those
receiving antiplatelet therapy alone and 43.7% of those receiving no antithrombotic therapy before
stroke shifted to OAC therapy. Yet, 37.5% of patients with stroke did not receive OAC therapy
following stroke. However, OAC treatment rates increased over time. During a maximum of 10 years
of follow-up, 17.5%, 21.2%, and 21.5% experienced a new thromboembolic event and 72.7%, 86.4%,
and 86.2% died among those treated with OAC therapy, antiplatelet therapy, or no antithrombotic
therapy, respectively. Poststroke OAC therapy was associated with lower risk of recurrent
thromboembolic events (adjusted hazard ratio, 0.81; 95% CI, 0.73-0.89) and no significant
difference in bleeding complications (adjusted hazard ratio, 0.97; 95% CI, 0.86-1.10), compared with
no poststroke antithrombotic therapy. In contrast, there were no significant differences for those
treated with poststroke antiplatelet therapy and no antithrombotic therapy.
(continued)
Key Points
Question Is oral anticoagulation
therapy used and effective for
secondary stroke prophylaxis in patients
with atrial fibrillation?
Findings In this cohort study of 30 626
intermediate- to high-risk patients with
atrial fibrillation having an ischemic
stroke, 36.3% received oral
anticoagulation therapy before their
stroke, and 52.5% received oral
anticoagulation therapy after their
stroke. Oral anticoagulation therapy was
associated with a statistically significant
reduction in thromboembolic risk.
Meaning There exists a major potential
for optimization of both primary and
secondary stroke prophylaxis in patients
with atrial fibrillation.
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Abstract (continued)
CONCLUSIONS AND RELEVANCE Patients with AF receiving poststroke OAC therapy had lower risk
of recurrent thromboembolic events. Our findings suggest a substantial opportunity for improving
primary and secondary stroke prophylaxis in high-risk patients with AF.
JAMA Network Open. 2018;1(1):e180171. doi:10.1001/jamanetworkopen.2018.0171
Introduction
Patients with atrial fibrillation (AF) have a 5-fold increased risk of ischemic stroke and 20% to 30%
of all strokes are generally attributed to AF.1-4 Oral anticoagulation (OAC) therapy with either vitamin
K antagonists or non–vitamin K antagonist oral anticoagulants reduces this risk by more than 60%
and is recommended as both primary and secondary stroke prophylaxis in patients with AF with at
least 1 to 2 risk factors for stroke according to the CHA2DS2-VASc (congestive heart failure;
hypertension; ages 74 years [2 points]; diabetes; stroke, transient ischemic attack, or systemic
embolism [2 points]; vascular disease; ages 65-74 years; sex [female]) risk score calculator.2,3,5-13
However, significant underuse of OAC therapy in patients with AF has been reported in both Europe
and the United States.14-22
In patients with AF who have experienced a stroke, the 90-day risk of early recurrence and long-
term recurrence have been reported to be 7.6% and approximately 18%, respectively.23,24 However,
studies regarding prestroke antithrombotic therapy in patients with AF presenting with stroke are
limited and data regarding poststroke antithrombotic therapy in patients with AF and the
relationship with the subsequent risk of stroke recurrence are sparse.21,25 To address these gaps in
knowledge, our aims were to examine prestroke and poststroke antithrombotic therapy in patients
with AF admitted with ischemic stroke and to compare long-term outcomes in AF stroke survivors
according to poststroke antithrombotic therapy.
Methods
Data Sources
The health care system in Denmark is tax financed and without any user charge (except for
medication outside the hospital). Data from 4 high-quality nationwide registries were linked using a
unique personal identifier number, which all residents are given at birth or immigration. The Danish
Civil Registration System holds information about sex, emigration, and date of birth and death.26
The Danish National Patient Registry holds information about all inpatient and outpatient hospital
contacts, including diagnoses and length of hospital stay.27 Diagnoses are registered in terms of
International Classification of Diseases codes (International Classification of Diseases, Eighth Revision
until 1994 and International Statistical Classification of Diseases and Related Health Problems, Tenth
Revision thereafter). The Danish Register of Causes of Death includes information about causes of
death.28 The Danish National Registry of Medicinal Statistics holds complete information about all
filled prescriptions in Denmark but does not hold information about in-hospital prescriptions.29
Approval from the research ethics committee system is not required in retrospective registry-based
studies in Denmark and a waiver is granted so that informed consent does not have to be obtained.
The Danish Data Protection Agency approved use of data for this study.
Study Patients
We identified all Danish residents with previously diagnosed AF (going back to 1978) who were
admitted to a Danish hospital with ischemic stroke (including ischemic stroke, unspecified stroke,
and transient ischemic attack [TIA]) from January 1, 2004, to January 31, 2017. According to
European AF guidelines, we excluded those younger than 30 years, with valvular AF, and with a
CHA2DS2-VASc score less than 1. The CHA2DS2-VASc score was calculated using a previously
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described method.30 The remaining patients composed the prestroke population. We also defined a
poststroke population that included those who survived a blanking period from hospital admission
for stroke until 100 days after discharge. The study index date was set 100 days from stroke
discharge to ensure complete information on poststroke antithrombotic treatment since packages
of antithrombotic therapy in Denmark include tablets for a maximum of 100 days of treatment.
Further, this blanking period ensured exclusion of those who died during their hospital admission for
stroke or shortly after. The patients were divided in subgroups according to poststroke
antithrombotic therapy and were followed up until June 30, 2017. In a sensitivity analysis, we
restricted the patient inclusion to patients with AF admitted with stroke, and therefore excluded
those admitted with TIA.
Antithrombotic Therapy
We divided the prestroke and poststroke study population into 3 study groups according to prestroke
and poststroke antithrombotic therapy: OAC therapy (including vitamin K antagonists and
non–vitamin K antagonist oral anticoagulants with or without concomitant antiplatelet therapy),
antiplatelet therapy alone (aspirin, adenosine diphosphate receptor inhibitors [clopidogrel,
prasugrel, and ticagrelor], and dipyridamole), and no antithrombotic therapy. Prestroke
antithrombotic therapy was defined as a filled prescription for antithrombotic therapy from 0 to 180
days before hospitalization for stroke. Poststroke antithrombotic therapy was defined as a filled
prescription for antithrombotic therapy during the blanking period (0-100 days after stroke
discharge). Due to differences in European and US guidelines, we performed a subgroup analysis of
prestroke treatment patterns in patients with a prestroke CHA2DS2-VASc score of 2 or greater. See
diagnosis codes and Anatomic Therapeutic Chemical Classification codes in eTable 1 in the
Supplement.
Outcomes
The poststroke population was followed up from the index date until an outcome of interest, end of
the study period (June 30, 2017), or emigration, whichever came first. The outcomes included
thromboembolic events (ischemic stroke, unspecified stroke, TIA, and embolism or thrombosis in
peripheral arteries), bleeding events, and death. Both AF and ischemic stroke were validated in the
Danish registries with a positive predictive value of 93% and 97%, respectively, and two-thirds of
unspecified strokes were classified as ischemic strokes by raters in a stroke validation study.31,32
Statistical Analysis
Patient demographic characteristics, comorbidities, CHA2DS2-VASc score, HAS-BLED (hypertension,
abnormal renal or liver function, history of stroke, history of bleeding, international normalized ratio
[left out due to missing data], ages 65 years, drug consumption with antiplatelet agents or
nonsteroidal anti-inflammatory drugs, alcohol abuse) risk score for bleeding, and concomitant
pharmacotherapy were assessed. The survival probability and cumulative incidence of
thromboembolic events according to poststroke antithrombotic therapy were calculated using the
Kaplan-Meier estimator and the Aalen-Johansen estimator (incorporating competing risk of death),
respectively. The Gray test was used to test for difference in cumulative incidence of
thromboembolic events. Crude and adjusted (age, sex, calendar year, comorbidities [ischemic heart
disease, peripheral artery disease, heart failure, coagulopathies, chronic kidney disease, chronic
obstructive pulmonary disease, alcohol abuse, diabetes, thyroid disease, hypertension, prior
bleeding events, pulmonary embolism, and deep venous thrombosis], and concomitant
pharmacotherapy [ β-blockers, digoxin, amiodarone, verapamil, and flecainide]) hazard ratios (HRs)
were calculated by Cox regression models comparing long-term outcomes according to poststroke
antithrombotic therapy. The Cox models were tested for proportional hazard assumptions and
linearity of continuous variables. Clinically relevant interactions (sex, calendar year, comorbidities,
CHA2DS2-VASc score, and HAS-BLED score) were assessed. Patient characteristics associated with
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prestroke and poststroke OAC therapy were assessed by multivariable logistic regression. A P value
less than .05 was considered statistically significant. All statistical analyses were performed in SAS
statistical software version 9.4 (SAS Institute Inc) or R software (R Foundation for Statistical
Computing).
Results
Prestroke Antithrombotic Therapy
Figure 1 depicts selection of the study population. From January 1, 2004, to January 31, 2017, 33 308
patients with AF presenting with ischemic stroke were admitted to Danish hospitals. After relevant
exclusions, the prestroke study population comprised 30 626 patients. Of these, 11 139 patients
(36.3%) received OAC therapy, 11 874 (38.8%) received antiplatelet therapy alone, and 7613 (24.9%)
did not receive any antithrombotic therapy before their stroke. Time trends in prestroke
antithrombotic treatment patterns are depicted in eFigure 1 in the Supplement. The annual
percentage of patients receiving OAC therapy before stroke ranged between 30.3% and 31.8% from
2004 to 2010. From 2010, this amount increased, reaching 58.5% in 2017.
The baseline characteristics of the prestroke study population according to prestroke
antithrombotic therapy are listed in the Table. Patients receiving OAC therapy were slightly younger
and less likely to be female (44.3% female; median age, 79 years [interquartile range {IQR}, 73-85
years]) than those who received antiplatelet therapy (55.0% female; median age, 82 years [IQR,
75-88 years]) or no antithrombotic therapy (53.8% female; median age, 80 years [IQR, 71-86 years])
before their hospital admission for stroke. No differences existed in CHA2DS2-VASc scores across the
different treatment groups. Patients receiving no antithrombotic therapy had a lower estimated
HAS-BLED score (median, 2 [IQR, 1-3]) than patients treated with either OAC (median, 3 [IQR, 2-4])
or antiplatelet therapy (median, 3 [IQR, 3-4]). When restricting the prestroke study population to
patients with a CHA2DS2-VASc score of 2 or greater, 10 757 patients (36.5%) received OAC therapy,
11 574 (39.3%) received antiplatelet therapy, and 7106 (24.1%) received no antithrombotic therapy
before their stroke diagnosis.
Poststroke Antithrombotic Therapy
Time trends in poststroke antithrombotic therapy are depicted in eFigure 2 in the Supplement. Over
the years, OAC treatment rates increased and reached 73.1% during the first 6 months of 2017. From
the day of hospital admission for stroke until the index date of 100 days after stroke hospitalization,
Figure 1. Patient Selection Flowchart
33 308 Patients with atrial fibrillation 
presenting with stroke January 1, 
2004, through January 31, 2017
2682 Excluded
106
1732
844
Aged >30 y and <99 y
Valvular atrial fibrillation
CHA2DS2-VASc score <1
30 626 Study population
11 139 Oral anticoagulation therapy
(with or without antiplatelet 
agent) (36.3%)
11 874 Antiplatelet therapy alone
(38.8%)
7613 No antithrombotic therapy 
(24.9%)
8927 Survivors to 100 d after 
discharge (80.1%)
8728 Survivors to 100 d after
discharge (73.5%)
5912 Survivors to 100 d after 
discharge (77.7%)
CHA2DS2-VASc indicates risk score for stroke
(congestive heart failure; hypertension; ages 74
years [2 points]; diabetes; stroke, transient ischemic
attack, or systemic embolism [2 points]; vascular
disease; ages 65-74 years; sex [female]).
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19.9%, 26.5%, and 22.3% of patients treated with OAC therapy, antiplatelet therapy, and no
antithrombotic therapy, respectively, before their stroke died. eTable 2 in the Supplement illustrates
patient characteristics at the index date for the poststroke population grouped by poststroke
antithrombotic therapy. Patients treated with OAC therapy following stroke compared with those
receiving antiplatelet therapy or no antithrombotic therapy were younger (median [IQR], 77 [70-83]
years, 82 [74-87] years, and 80 [74-87] years, respectively), had a lower CHA2DS2-VASc risk score
(median [IQR], 5 [4-6], 6 [5-6], and 5 [4-6], respectively), and had a lower HAS-BLED risk score
(median [IQR], 4 [3-4], 4 [4-5], and 3 [3-4], respectively).
Prestroke to Poststroke Change in Antithrombotic Therapy
Treatment shifts from before stroke to after stroke among the poststroke population are depicted in
Figure 2. The proportion of patients receiving OAC therapy increased from before stroke to after
stroke (36.3% vs 52.5%). Of those treated with OAC therapy, antiplatelet therapy, or no
antithrombotic therapy before their hospital admission for stroke, 79.0%, 58.7%, and 16.9%,
respectively, continued to receive the same treatment after discharge. Following stroke, 31.3% of
those receiving antiplatelet therapy alone and 43.7% of those receiving no antithrombotic therapy
before stroke shifted to OAC therapy. Yet, 37.5% of patients with stroke did not receive OAC therapy
following stroke.
Table. Baseline Characteristics at Stroke Hospital Admission According to Prestroke Antithrombotic Therapy
in the Prestroke Population
Characteristic
No. (%)
Overall
(N = 30 626)
OAC Therapy
(n = 11 139)a
Antiplatelet Therapy
Alone (n = 11 874)b
No Antithrombotic
Therapy (n = 7613)
Demographic
Age, median (IQR), y 81 (73-86) 79 (73-85) 82 (75-88) 80 (71-86)
Female 15 563 (50.8) 4937 (44.3) 6527 (55.0) 4099 (53.8)
Comorbidities
Alcohol abuse 1419 (4.6) 411 (3.7) 568 (4.8) 440 (5.8)
Cancer 5597 (18.3) 2167 (19.5) 2045 (17.2) 1385 (18.2)
Coagulopathies 636 (2.1) 339 (3.0) 166 (1.4) 131 (1.7)
Chronic kidney disease 2349 (7.7) 912 (8.2) 961 (8.1) 476 (6.3)
Chronic obstructive
pulmonary disease
4143 (13.5) 1578 (14.2) 1680 (14.2) 885 (11.6)
Deep venous thrombosis 1245 (4.1) 596 (5.4) 397 (3.3) 252 (3.3)
Dementia 1677 (5.5) 417 (3.7) 921 (7.8) 339 (4.5)
Diabetes 4836 (15.8) 2089 (18.8) 1925 (16.2) 822 (10.8)
Heart failure 7913 (25.8) 3290 (29.5) 3198 (26.9) 1425 (18.7)
Hypertension 19 363 (63.2) 8090 (72.6) 7850 (66.1) 3423 (45.0)
Ischemic heart disease 11 099 (36.4) 4144 (37.2) 5274 (44.4) 1681 (22.1)
Peripheral artery disease 2734 (8.9) 1073 (9.6) 1252 (10.5) 409 (5.4)
Prior bleeding event 7963 (26.0) 3110 (27.9) 2935 (24.7) 1918 (25.2)
Prior thromboembolic
event
11 585 (37.8) 4267 (38.3) 4558 (38.4) 2760 (36.3)
Pulmonary embolism 770 (2.5) 414 (3.7) 191 (1.6) 165 (2.2)
Risk scores, median (IQR)
CHA2DS2-VAScc 4 (3-5) 4 (3-5) 4 (3-5) 4 (3-5)
HAS-BLEDd 3 (2-4) 3 (2-4) 3 (3-4) 2 (1-3)
Pharmacotherapy
Amiodarone 795 (2.6) 425 (3.8) 291 (2.5) 79 (1.0)
β-Blockers 16 056 (52.4) 6920 (62.1) 6422 (54.1) 2714 (35.7)
Digoxin 9580 (31.3) 4426 (39.7) 3677 (31.0) 1477 (19.4)
Flecainide 292 (1.0) 131 (1.2) 101 (0.9) 60 (0.8)
Verapamil 2356 (7.7) 1078 (9.7) 880 (7.4) 398 (5.2)
Abbreviations: IQR, interquartile range; OAC, oral
anticoagulation.
a Includes vitamin K antagonists and non–vitamin K
OAC with or without antiplatelet agent.
b Includes aspirin, adenosine diphosphate receptor
inhibitors (clopidogrel, prasugrel, and ticagrelor), and
dipyridamole.
c Risk score for stroke: congestive heart failure;
hypertension; ages 74 years or older (2 points);
diabetes; stroke, transient ischemic attack, or
systemic embolism (2 points); vascular disease; ages
65 to 74 years; sex (female).
d Risk score for bleeding: hypertension, abnormal
renal or liver function, history of stroke, history of
bleeding, international normalized ratio (left out due
to missing data), ages 65 years or older, drug
consumption with antiplatelet agents or
nonsteroidal anti-inflammatory drugs,
alcohol abuse.
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Long-term Outcomes According to Poststroke Antithrombotic Therapy
The median follow-up time from the index date to study outcome, death, emigration, or study end
was 2.2 years (IQR, 0.8-4.6 years). Figure 3 shows the cumulative incidence of thromboembolic
events and deaths according to poststroke antithrombotic therapy. During a maximum of 10 years of
follow-up, 17.5%, 21.2%, and 21.5% experienced a new thromboembolic event and 72.7%, 86.4%,
and 86.2% died among those treated with OAC therapy, antiplatelet therapy, or no antithrombotic
therapy, respectively.
The long-term risks of stroke (adjusted HR, 0.81; 95% CI, 0.73-0.89) and death (adjusted HR,
0.68; 95% CI, 0.65-0.72) were significantly lower among patients treated with OAC therapy
compared with no antithrombotic therapy (Figure 4). In contrast, no significant differences existed
for those treated with antiplatelet therapy compared with no antithrombotic therapy
(thromboembolic event: adjusted HR, 1.01; 95% CI, 0.92-1.12; death: adjusted HR, 0.95; 95% CI, 0.91-
1.00). When comparing the long-term risk of bleeding events according to poststroke antithrombotic
therapy, no statistically significant differences were found for OAC therapy (adjusted HR, 0.97; 95%
CI, 0.86-1.10) compared with no antithrombotic therapy. The restriction of the study population to
patients with a prestroke CHA2DS2-VASc score of 2 or greater did not change the results (eFigure 3 in
the Supplement).
When excluding patients admitted with TIA, the prestroke population consisted of 26 708
patients. With regard to long-term outcomes, the results were similar to those from the main analysis
(eFigure 4 in the Supplement).
Figure 2. Prestroke to Poststroke Shifts in Antithrombotic Therapy Among Poststroke Study Population
Oral anticoagulation
n = 11 139 (36.3%)
Antiplatelet alone
n = 11 874 (38.8%)
No antithrombotic therapy 
n = 7613 (24.9%)
Stroke Index date
2212 Deaths 
(19.9%)
3146 Deaths
(26.5%)
1701 Deaths
(22.3%)
7049 (79.0%)
921 (10.3%)957 (10.7%)
2732 (31
.3%)
5127 (58.7%)
869 (10.0%)
2585
 (43.
7%)
2330 (39
.4%)
997 (16.9%)
Oral anticoagulation
n = 12 366 (52.5%)
Antiplatelet alone
n = 8378 (35.5%)
No antithrombotic therapy 
n = 2823 (12.0%)
Figure 3. Thromboembolic Events and Death by Poststroke Treatment Group
25
20
15
10
5
0
0 2 4 108
Th
ro
m
bo
em
bo
lic
 E
ve
nt
, %
Years Since Stroke
6
Thromboembolic eventsA
No. at risk
Oral anticoagulation
Antiplatelet
No antithrombotic
12 366
8378
2823
9365
5730
1891
7187
4291
1423
5458
3206
1077
4141
2413
800
3072
1777
604
2253
1302
471
1685
940
345
1228
628
255
837
414
181
579
270
115
No antithrombotic
Antiplatelet
Oral anticoagulation
100
75
50
25
0
0 2 4 108
De
at
h,
 %
Years Since Stroke
6
DeathB
No. at risk
Oral anticoagulation
Antiplatelet
No antithrombotic
12 366
8378
2823
9800
6189
2041
7685
4806
1601
5916
3694
1245
4541
2790
951
3386
2057
717
2496
1501
558
1862
1071
400
1350
719
299
927
476
203
625
309
129
No antithrombotic
Antiplatelet
Oral anticoagulation
A, Cumulative incidence of thromboembolic events. B, Kaplan-Meier curve for death.
JAMA Network Open | Cardiology Antithrombotic Therapy and Long-term Outcomes in Patients With Atrial Fibrillation and Ischemic Stroke
JAMA Network Open. 2018;1(1):e180171. doi:10.1001/jamanetworkopen.2018.0171 May 18, 2018 6/12
Downloaded From:  by a Aalborg University Hospital User  on 12/21/2018
Factors Associated With OAC Therapy
Factors associated with prestroke and poststroke OAC therapy are depicted in eFigure 5 and
eFigure 6 in the Supplement. For the analysis of the prestroke population, being male, being older
than 74 years, and several comorbidities (coagulopathies, deep venous thrombosis, diabetes, heart
failure, hypertension, ischemic heart disease, peripheral artery disease, and pulmonary embolism)
were associated with OAC therapy, and alcohol abuse, chronic kidney disease, dementia, and prior
bleeding events were associated with no OAC therapy. The CHA2DS2-VASc score was not associated
with the prestroke treatment category. For the poststroke analysis, ages 65 to 74 years (compared
with ages <65 years), being male, deep venous thrombosis, and hypertension were associated with
OAC therapy. Ages greater than 74 years, alcohol abuse, cancer, chronic kidney disease, chronic
obstructive pulmonary disease, dementia, ischemic heart disease, and prior bleeding events were
associated with no OAC therapy.
Discussion
We examined prestroke and poststroke antithrombotic therapy in patients with AF with a
CHA2DS2-VASc score of 1 or greater presenting with ischemic stroke, and further related treatment
patterns with subsequent long-term outcomes. The study yielded 4 main findings. First, before
stroke, almost two-thirds of patients with AF did not receive OAC therapy as recommended by
guidelines. Second, after stroke about half of the stroke survivors did not receive OAC therapy.
However, prestroke and poststroke treatment rates increased over time. Third, approximately 1 of 5
of those who survived a stroke had a new stroke during follow-up (median, 2.2 years). Fourth,
poststroke OAC therapy was associated with a significantly lower risk of a new thromboembolic
event without increased risk of bleeding complications compared with antiplatelet therapy or no
poststroke antithrombotic therapy. Taken together, these findings suggest substantial opportunities
for improvement of both primary and secondary stroke prevention in intermediate- to high-risk
patients with AF.
Prestroke Antithrombotic Therapy
The prestroke use of OAC increased over time, reaching 58.5% in 2017. During the 1990s, several
studies showed benefits from OAC therapy (with vitamin K antagonists) instead of aspirin for
thromboprophylaxis in patients with AF.33-36 European guidelines changed in 2010, recommending
OAC therapy and not aspirin for stroke prevention in patients with AF.37 Since then, an increase of
OAC therapy has been observed in Denmark among patients with AF,17 which is in accordance with
this study. Nevertheless, the percentage of eligible patients not receiving any antithrombotic therapy
remained approximately 23% even after the new guideline recommendations. Because patients had
to pick up the medication at a pharmacy to be registered in a treatment group, bad compliance may
Figure 4. Incidence Rates and Adjusted Hazard Ratios of Long-term Outcomes (Thromboembolic Event
and Death) According to Poststroke Treatment
Poststroke
Antithrombotic
Therapy
Incidence
Rate/1000 
Person-Years
Adjusted Hazard 
Ratio (95% CI)Person-YearsEvents, No.Long-term Outcome
No Poststroke
Antithrombotic
Therapy
2.01.00.5
Adjusted Hazard Ratio (95% CI)
Thromboembolic event
No antithrombotic
Antiplatelet
Oral anticoagulation
538
1578
1566
8547
25 020
42 262
62.9
63.1
37.1
1 [Reference]
1.01 (0.92-1.12)
0.81 (0.73-0.89)
Death
No antithrombotic
Antiplatelet
Oral anticoagulation
2044
6059
5640
9581
27 771
45 158
213.3
218.2
124.9
1 [Reference]
0.95 (0.91-1.00)
0.68 (0.65-0.72)
Covariates in the adjusted model included age at study
start, sex, calendar year, comorbidities (ischemic heart
disease, peripheral artery disease, heart failure, prior
pulmonary embolism, prior deep venous thrombosis,
coagulopathies, chronic kidney disease, prior bleeding
event, alcohol abuse, diabetes, hypertension, and
chronic obstructive pulmonary disease), and
concomitant pharmacotherapy (including β-blockers,
digoxin, amiodarone, verapamil, and flecainide).
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have accounted for some part of the patients in the group receiving no antithrombotic therapy.
Recently, Xian et al13 investigated prestroke antithrombotic therapy in patients with AF presenting
with acute ischemic stroke and the association with stroke severity in the Patient-Centered Research
Into Outcomes Stroke Patients Prefer and Effectiveness Research study including national stroke
data from the United States.21,38 In that cohort, approximately 30% received OAC therapy before
their stroke diagnosis, 40% received antiplatelet therapy alone, and 30% did not receive any
prestroke antithrombotic therapy. These findings are consistent with ours, although Xian and
colleagues13 were unable to study subsequent treatment patterns and outcomes.
Poststroke Antithrombotic Therapy
After stroke, 1 in 3 of those who received antiplatelet therapy before stroke shifted to OAC therapy,
while almost half of those with no prestroke antithrombotic therapy shifted to OAC therapy. Despite
this, almost half of the poststroke population still did not receive OAC therapy. However, treatment
rates increased over time. Unfortunately, we had no data on contraindications for OAC therapy and
physicians’ considerations when choosing not to prescribe OAC therapy at discharge. In the recent
study by Xian et al13 using data from the Get With the Guidelines–Stroke program with access to
patient files, the most common reasons not to prescribe OAC therapy in patients with AF after stroke
were risk of bleeding (16.3%), risk of falls (10.3%), and terminal illness (6.2%). However, 65.8% of
the patients did not have a documented reason for no OAC therapy.21
In previous studies, we found an association between older age, higher HAS-BLED score, and
more comorbidities and no poststroke OAC therapy.39,40 This could reflect a caution among
physicians in the prescription of OAC therapy for older patients, even though they are at high risk of
stroke. However, Appelros and colleagues39 recently showed a beneficial effect of OAC therapy for
stroke prophylaxis in patients older than 80 years.
Recurrent Thromboembolic Events
Several studies have examined early recurrence in patients with AF presenting with stroke,23,41,42 and
a few have looked into the long-term risks.24,39,43 Wu et al24 found a stroke recurrence rate among
patients with AF of 18% during a median follow-up of 2.4 years from stroke hospitalization. This is in
accordance with our finding. Patients receiving OAC therapy had a significantly lower risk of a
recurrent thromboembolic event compared with those receiving no antithrombotic therapy. Further,
no decrease in thromboembolic risk was found for those receiving poststroke antiplatelet therapy.
This in part may be related to the possible effectiveness of OAC therapy as secondary stroke
prevention in patients with AF. Our results also showed an association between poststroke OAC
therapy and lower risk of death. Regarding bleeding events, no significant differences were found
across treatment groups. This may be because of residual confounding and confounding by
indication, which should be kept in mind when interpreting our results.
Limitations
This was a retrospective observational study, and no causations can be drawn. Our registries did not
include factors such as alcohol consumption or fall tendency. Also, all types of AF were included in
the study, and hence also AF occurring secondary to other conditions (eg, postoperative AF). These
are factors that may influence the physicians’ choice of antithrombotic therapy. Also, no information
on labile international normalized ratio was available for this population, possibly leading to an
overestimation of patients receiving adequate OAC therapy. The Danish National Registry of
Medicinal Statistics registers redeemed prescriptions, and patients had to pick the medication up to
be included in either the OAC or antiplatelet therapy group. Therefore, our results may have been
influenced by patient compliance. Moreover, the definition of ischemic stroke included TIA and
strokes without classification as hemorrhagic or thrombotic. This may have led to some degree of
misclassification. To ensure complete data on antithrombotic therapy, we constructed a blanking
period from hospital discharge to 100 days following stroke. During this blanking period several
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patients died and some of the patients likely had a recurrent thromboembolic event or experienced
a bleeding event. This may have led to underestimation of events in the poststroke population.
Importantly, this study was based on very high-quality data with nationwide patient inclusion and
complete and long-term follow-up ensuring an unbiased selection of study group without loss of
follow-up.
Conclusions
Among patients with AF having an ischemic stroke, OAC therapy rates seemed low both before and
after stroke. However, an increase in treatment rates was observed over time. Oral anticoagulation
therapy was associated with a significantly lower risk of thromboembolic events without excess risk
of bleeding complications compared with antiplatelet therapy and no antithrombotic therapy. This
study suggests a substantial opportunity for improving primary and secondary stroke prophylaxis in
patients with AF.
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